Source comparison
Tolerance to MOTS-c Cycling: Research Compound Comparison
MOTS-c AMPK activation, mitochondrial biogenesis 8–12 weeks continuous use 8–12 weeks on, 4–6 weeks off 4–6 weeks for full receptor density restoration Requires structured cycling to maintain efficacy; tolerance is receptor-mediated, not pharmacological Humani
This comparison does not assign a generated winner or score.
- MOTS-c
- AMPK activation, mitochondrial biogenesis
- 8–12 weeks continuous use
- 8–12 weeks on, 4–6 weeks off
- 4–6 weeks for full receptor density restoration
- Requires structured cycling to maintain efficacy; tolerance is receptor-mediated, not pharmacological
- Humanin
- Anti-apoptotic signaling, neuroprotection
- 12–16 weeks continuous use
- 12 weeks on, 4 weeks off
- 3–4 weeks for receptor normalisation
- Slower tolerance development than MOTS-c; cytoprotective effects persist longer
- SS-31 (Elamipretide)
- Cardiolipin binding, mitochondrial membrane stabilisation
- Minimal tolerance observed in studies up to 24 weeks
- Continuous administration viable
- Not typically required
- Direct membrane action reduces receptor-mediated tolerance; most consistent long-term profile
- NAD+ Precursors (NMN/NR)
- NAD+ repletion, sirtuin activation
- Plateau at 8–10 weeks due to salvage pathway saturation
- 8 weeks on, 2–4 weeks off
- 2–3 weeks for enzyme normalisation
- Tolerance relates to enzyme saturation, not receptor downregulation; shorter washout sufficient